Stockscreener 앱 받기
0.15%
시간 외 거래:
전일 마감가:
$26.14
열려 있는:
$26.19
하루 거래량:
48.41M
Relative Volume:
1.31
시가총액:
$149.21B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
20.07
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
+1.08%
1개월 성능:
-0.30%
6개월 성능:
+1.71%
1년 성능:
+11.64%
1일 변동 폭
$25.93
$26.24
1주일 범위
$25.66
$26.54
52주 변동 폭
$23.06
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.18 | 148.98B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Comirnaty and Pfizer's mRNA vaccine in the U.S. market - AD HOC NEWS
Is Pfizer Stock a "Value Trap" or a Generational Opportunity? - Yahoo Finance
Pfizer (PFE) Reports Promising Results from Breakwater Trial - GuruFocus
Pfizer (PFE) Unveils Promising Talzenna Study Results for Prosta - GuruFocus
Pfizer Inc. stock (US7170811035): TALZENNA plus XTANDI data and stakeholder moves keep focus on onco - AD HOC NEWS
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies - Yahoo Finance
Why Wall Street Is Dead Wrong About This Popular Stock - The Motley Fool
Pfizer says Talzenna plus Xtandi improves radiographic progression-free survival by over 50% in metastatic prostate cancer - marketscreener.com
Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation - simplywall.st
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing - MedCity News
Pfizer, HP among top 10 large-cap value stocks - MSN
Pfizer Inks Up to $10.5B Innovent Biotech Licensing Deal - Gotrade
Pfizer School of Science Mobile Experience Makes STEM Learning Fun - PIX11
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market - TipRanks
Pfizer says EC authorizes update to pediatric use of Pfizer & BioNTech Covid 19 vaccine - marketscreener.com
Pfizer Inc. stock (US7170811035): Oncology deal with Innovent reshapes pipeline focus - AD HOC NEWS
Pfizer (PFE) Reveals Promising Seven-Year Findings from CROWN Tr - GuruFocus
Pfizer (PFE) Among Most Attractively Valued U.S. Stocks - GuruFocus
Pfizer, Innovent strike $10B cancer drug deal - BioPharma Dive
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal - GuruFocus
Turning Silence Into Advocacy: Women Reshaping Cancer Conversations - Pfizer
Pfizer's Lorbrena Shows 55% Likelihood of Progression-Free Survival After Seven Years in NSCLC Study - marketscreener.com
Pfizer, Innovent Strike $10.5 Billion Oncology Deal to Develop 12 Cancer Medicines - Contract Pharma
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer - Business Wire
Pfizer and Innovent Biologics sign $10.5B cancer drug deal - Yahoo Finance
Pfizer partners with Innovent for $10.5bn to advance ADC oncology medicines - European Pharmaceutical Review
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal - Pharmaceutical Technology
Pfizer and China's Innovent sign major deal on cancer treatment - medwatch.com
Pfizer (PFE) Partners with Innovent Biologics in $10.5B Oncology Deal - GuruFocus
PFE Stock Quote Price and Forecast - CNN
Pfizer, Innovent Biologics Strike Cancer Drug Partnership Worth up to $10.5 Billion - marketscreener.com
Pfizer signs up to $10.5B oncology deal with China’s Innovent (PFE:NYSE) - Seeking Alpha
Innovent Biologics and Pfizer Joint Development of 12 Oncology ProgrammesNews and Statistics - IndexBox
Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom - WKZO
Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics - BusinessLine
Innovent Biologics, Pfizer strike US$10.5 bil cancer drug deal amid China biotech boom - The Edge Malaysia
Pfizer Inks Up to $10.5 Billion Deal With China’s Innovent - Bloomberg.com
INNOVENT BIO Leaps ~8% on Strategic Collaboration with Pfizer Covering 12 Projects - AASTOCKS.com
INNOVENT BIO Forms Strategic Collaboration with Pfizer on 12 Projects with Total Deal Value of USD10.5B - AASTOCKS.com
Pfizer inks up to $10.5 billion deal With China’s Innovent - Moneycontrol.com
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - The Manila Times
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal - Reuters
Should Pfizer’s (PFE) New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors? - simplywall.st
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - Business Wire
Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs - marketscreener.com
Wardlaw+Hartridge Student Receives Pfizer Scholarship - TAPinto
Pfizer’s New Phase 1 Trial Signals Steady Early-Stage Pipeline Progress - TipRanks
For this Pfizer Scientist, Cancer Research is Personal - Pfizer
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.31%
0.09%
자본화:
|
볼륨(24시간):